Drug Profile

bbT 4015

Alternative Names: bbT-4015

Latest Information Update: 03 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator bluebird bio; Regeneron Pharmaceuticals
Developer 2seventy bio; Regeneron Pharmaceuticals
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

01 Apr 2024 Regeneron Pharmaceuticals acquires anti-cancer immune cell therapies from 2seventy bio
30 Jan 2024 Regeneron plans to Acquire anti-cancer cell therapies from 2seventy bio in the first half 2024
31 Dec 2023 Regeneron Pharmaceuticals submits an IND for bbT 4015 in Ovarian cancer in late December 2023

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com